LMR Partners’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$633K Hold
35,000
﹤0.01% 1059
2025
Q4
$761K Sell
35,000
-10,000
-22% -$286K ﹤0.01% 1049
2025
Q3
$1.47M Sell
45,000
-15,000
-25% -$554K 0.01% 831
2025
Q2
$2.13M Buy
+60,000
New +$1.94M 0.02% 626
2025
Q1
Sell
-67,200
Closed -$2.19M 1521
2024
Q4
$2.19M Sell
67,200
-57,200
-46% -$2.37M 0.02% 577
2024
Q3
$6.06M Sell
124,400
-2,600
-2% -$138K 0.05% 317
2024
Q2
$5.62M Buy
127,000
+25,100
+25% +$1.16M 0.05% 300
2024
Q1
$5.72M Buy
101,900
+15,200
+18% +$917K 0.06% 290
2023
Q4
$5.22M Buy
86,700
+11,797
+16% +$748K 0.06% 297
2023
Q3
$5.03M Buy
74,903
+2,703
+4% +$188K 0.06% 251
2023
Q2
$4.98M Sell
72,200
-18,600
-20% -$1.22M 0.06% 251
2023
Q1
$4.38M Buy
90,800
+19,500
+27% +$954K 0.07% 291
2022
Q4
$3.56M Buy
71,300
+15,000
+27% +$727K 0.06% 346
2022
Q3
$2.3M Hold
56,300
0.04% 490
2022
Q2
$3.1M Buy
56,300
+32,749
+139% +$1.38M 0.05% 393
2022
Q1
$856K Buy
23,551
+13,050
+124% +$516K 0.01% 867
2021
Q4
$489K Buy
+10,501
New +$533K 0.01% 902

Other funds holding LEGN

LMR Partners's LEGN Position: Q1 2026 in Review

LMR Partners held its Legend Biotech (LEGN) position steady in Q1 2026 at 35,000 shares worth $633K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

LMR Partners first reported a position in LEGN in Q4 2021 and has held it in 17 quarters since. The position peaked at $6.06M in Q3 2024. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • LMR Partners held 35,000 shares of Legend Biotech worth $633K as of Q1 2026.
  • LMR Partners left its Legend Biotech share count unchanged in Q1 2026.
  • Legend Biotech made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1059 holding.
  • LMR Partners first reported a position in Legend Biotech in Q4 2021 and has held it in 17 quarters since.
  • LMR Partners's Legend Biotech position peaked at $6.06M in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.